# BTC-BGB (NCT04727996)

> Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04727996
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Seoul National University Hospital
- Conditions: Advanced Biliary Tract Cancer
- Interventions: Sitravatinib; Tislelizumab
- Enrollment: 43
- Primary outcome: Disease control rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=btc-bgb-nct04727996